Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.
1/5 보강
[This corrects the article DOI: 10.3389/fendo.2022.822423.].
APA
Zha X, Miao Z, et al. (2022). Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.. Frontiers in endocrinology, 13, 911963. https://doi.org/10.3389/fendo.2022.911963
MLA
Zha X, et al.. "Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.." Frontiers in endocrinology, vol. 13, 2022, pp. 911963.
PMID
35663313 ↗
Abstract 한글 요약
[This corrects the article DOI: 10.3389/fendo.2022.822423.].
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Does protocol heterogeneity in active surveillance influence clinical outcomes? Insights from a multicenter prostate cancer cohort.
- European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.
- Association of Socioeconomic Position, Prostate-specific Antigen, and Age with Observation in Low-risk Prostate Cancer Patients in Switzerland.
- Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).
- A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance.
- A cognitive divide in active surveillance acceptance persists between surgeons and endocrinologists managing low-risk thyroid cancer.